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patients had a prescription ﬁlled for a beta-blocker during 2002.
Of the CHF patients receiving a beta-blocker, less than 45% were
prescribed either of the two indicated agents (carvedilol or
extended-release metoprolol succinate) for CHF. Furthermore,
less than 40% of patients prescribed either carvedilol or
extended-release metoprolol succinate achieved target CHF
doses. Thus, of those CHF patients currently on beta-blocker
therapy, less than 17% received an appropriate regimen. CON-
CLUSIONS: This evaluation illustrates that less than ten percent
of CHF patients in this managed care plan are receiving optimal
beta-blocker therapy. Future quality improvement efforts should
be focused on provider-based educational initiatives to improve
beta-blocker prescribing patterns in the CHF population.
Increased use of beta-blocker therapy in patients identiﬁed with
CHF would signiﬁcantly improve the morbidity and mortality
associated with this disease.
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OBJECTIVES: To investigate statin usage patterns in terms of
termination, switch and/or augmentation, and to associate these
patterns with changing market conditions. METHODS: The
study is based on a 20% sample of California Medicaid (Medi-
Cal) fee-for-service claims on statin prescriptions from 1995
through 2002. The length of the ﬁrst statin therapy phase is pre-
sented with Kaplan-Meier curves. The switch and/or augmenta-
tion pattern is studied by tracking each patient for 12 months
from the date of the ﬁrst ﬁll (index date). Results are presented
by the year of index date. There are six statins included in the
study: Cerivastatin, Fluvastatin, Atorvastatin, Lovastatin,
Pravastatin and Simvastatin. RESULTS: Atorvastatin (N =
15,686, Median survival days = 244) and Simvastatin (N = 9162,
Median survival days = 200) had longer therapy phases while
Cerivastatin (N = 2022, Median survival days = 101) and Lovas-
tatin (N = 8910, Median survival days = 99) had shorter therapy
phases. About 40% of Atorvastatin and Simvastatin patients
were still on their initial medication after one year, but only 20%
of patients initiated on Lovastatin or Cerivastatin remained on
their medication. The introduction of Atorvastatin was associ-
ated with a sudden increase of switch/augmentation events
among patients initiated on other statin brands. When Cerivas-
tatin was withdrawn from the US market and Lovastatin was
phased out of the Medi-Cal formulary, the proportion of
switch/augmentation events also increased. CONCLUSIONS:
The introduction of Atorvastatin, the withdrawal of Cerivastatin
and the phase-out of Lovastatin may be key factors in statin per-
sistence patterns. Market forces should not be overlooked when
analyzing medication compliance and medication usage patterns.
Because changes in the market are more likely to be unique
events, their effect may overshadow other adjustments in 
comparison of medication compliance.
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OBJECTIVES: To analyze the changes in utilization and pre-
scribing patterns of antihypertensive drugs before and after the
publication of the ALLHAT results in 2002 that recommended
the use of thiazide diuretics in new starts. METHODS: Utilizing
pharmacy claims, member and provider data from a managed
care plan of over 2 million members, this study selected two
cohorts of patients who received two or more claims for anti-
hypertensive or diuretic products from the same providers in the
ﬁrst 9 months of 2002 (Period 1) or the ﬁrst 9 months of 2003
(Period 2). The providers who prescribed antihypertensive or
diuretic medications for both periods were included. The patients
were continuously enrolled adults who did not receive any anti-
hypertensive or diuretic products in the 3 months prior to index
date. Changes in physician prescribing patterns for initiation of
hypertension treatment in Period 1 and Period 2 were analyzed.
Utilization of different medications between the two periods,
especially the likelihood of receiving thiazide diuretics, was also
examined. RESULTS: The study identiﬁed 7605 physicians who
prescribed antihypertensive drugs to 25,519 patients in Period 1
and 26,300 patients in Period 2. Across the two periods, the per-
centage of physicians who prescribed any thiazide diuretics
increased from 14.5% to 16.1% (p < 0.01), while utilization of
ACE inhibitors or CCBs as initial treatment decreased approxi-
mately 2% (p < 0.01). A logistic regression model indicated that
patients in Period 2 were 22.8% more likely to receive thiazide
diuretics and 9.9% more likely to receive any diuretics than
patients in Period 1 (p < 0.01), controlling for demographics,
comorbidities measured by chronic disease scores (CDS), 
and provider specialties. CONCLUSION: ALLHAT results
increased prescribing of thiazide diuretics as initial treatment of
hypertension.
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OBJECTIVE: The NSF guidelines for CAD, introduced in March
2000 in the UK, advocate that by April 2002, 80–90% of the
patients discharged from hospital following myocardial infarc-
tion (MI) should be receiving prescriptions for aspirin and statins
for secondary prevention. A time-trend analysis was performed
to assess the impact of NSF on physician compliance with the
prescribing guidelines. METHODS: The UK-Mediplus, a nation-
ally representative general-practitioner database was used to
identify all individuals with diagnosis of their ﬁrst MI (index-
date) between April 1997 and March 2003, and surviving at least
90 days following the index-date. Patients receiving at least one
prescription of statin and aspirin, linked to their MI diagnosis,
during the 90-day follow-up period were considered NSF-com-
pliant with those drugs respectively. Annual trends in proportion
of NSF-compliant patients, for aspirin, statins and aspirin-statin
combination, were compared between pre- and post-NSF (after
March 2000) periods. Logistic regression was used to estimate
the effect of age and gender on compliance. RESULTS: Of 8598
eligible ﬁrst-MI patients with a mean age of 70.4 (S.D. = 13.2),
65.5% were males, and 67.2% were elderly (age 65+). Aspirin-
statin combination use increased from 13.7% to 23.5% between
April 1997 and March 2000, and increased to 42.1% by March
2003. Aspirin and statin use alone were 49.5% and 71.6%
respectively by end of March 2003. Relative to non-elderly, the
elderly were less likely to receive aspirin-statin combination.
However, the odds ratio (OR) for the elderly receiving combi-
nation improved during post-NSF period (OR = 0.64, p < 0.05
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vs. OR = 0.47, p < 0.05). Compliance between males and females
remained similar in both periods (p > 0.05). CONCLUSION:
Despite signiﬁcant improvement in recent years, the proportion
of post-MI patients in UK, particularly the elderly, receiving
aspirin-statin combination is signiﬁcantly less than the NSF
treatment goals. Intensive dissemination efforts are required to
achieve greater impact of this policy.
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OBJECTIVE: It is known that initiation of drug therapy for
hypercholesterolaemia once diagnosed, is improving and now
stands at around 60%. What is unclear is whether there is a delay
between patients being identiﬁed with elevated cholesterol and a
subsequent diagnosis of hypercholesterolaemia. To address this
uncertainty, this database study followed patients with an initial
recording of cholesterol greater than 5mmol/L, through diagno-
sis and advice to treatment. METHODS: The DIN-LINK data-
base, containing anonymised medical records from 1.5 million
patients collected via GP practice computers, was used to iden-
tify and follow-up a cohort of patients with a recorded choles-
terol level greater than 5mmol/L. For inclusion, each patient had
to have a baseline measurement taken between April 2001 and
April 2002, a minimum of 12 months follow-up data and not
been diagnosed with hypercholesterolaemia or be prescribed
cholesterol lowering medications prior to the cholesterol mea-
surement. RESULTS: A total of 3418 patients were identiﬁed as
meeting the criteria. Of these, 991 (29%) were diagnosed as
hypercholesterolaemic within 12 months, three-quarters of these
on the same date as the recording of the elevated cholesterol. Of
the initially identiﬁed 3418 patients, only 257 (8%) were pre-
scribed cholesterol lowering medication within 12 months of the
initial reading. CONCLUSIONS: For patients who are known
to have elevated cholesterol 71% fail to receive a diagnosis of
hypercholesterolaemia and 92% do not receive medication
within 12 months of initial reading. Further analyses are required
to determine the impact of these delays in diagnosis on patient
outcomes.
PCV56
DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF
TREATMENT FOR HYPERTENSION
O’Regan CP1, Lister SP2, Marchant NJ1
1Pﬁzer UK Limited, Walton on the Hill, United Kingdom; 2Compuﬁle
Limited, Woking, United Kingdom
OBJECTIVE: It is known that initiation of drug therapy for
hypertension, once diagnosed, is now relatively high at around
85%. What is unclear is whether there is a delay between
patients being identiﬁed with elevated blood pressure and a sub-
sequent diagnosis of hypertension. To address this uncertainty,
this database study followed patients with an initial recording of
systolic blood pressure greater than 150mmHg, through diag-
nosis and advice to treatment. METHODS: The DIN-LINK
database, containing anonymised medical records from 1.5
million patients collected via GP practice computers, was used
to identify and follow-up a cohort of patients with a recorded
systolic blood pressure greater than 150mmHg. For inclusion
each patient had to have a baseline measurement taken between
April 2001 and April 2002, a minimum of 12 months follow-up
data and not been diagnosed with hypertension or be prescribed
antihypertensive medications prior to the blood pressure 
measurement. RESULTS: A total of 2880 patients were identi-
ﬁed as meeting the criteria. Of these, 1469 (51%) were diagnosed
as hypertensive within 12 months, two-thirds of these within one
month of the recording of elevated blood pressure. Of the 
initially identiﬁed 2880 patients, only 579 (20%) were pre-
scribed blood pressure lowering medication within 12 months of
the initial reading. CONCLUSIONS: For patients who are
known to have an elevated blood pressure 49% fail to receive a
diagnosis of hypertension and 80% do not receive medication
within 12 months of initial reading. Further analyses are required
to determine the impact of these delays in diagnosis on patient
outcomes.
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OBJECTIVES: To evaluate associations between insurance cov-
erage and length of stay, death, and discharge destination of
patients hospitalized for non-hemorrhagic stroke. METHODS:
A retrospective analysis was conducted of patients hospitalized
for <30 days with a primary diagnosis of nonhemorrhagic stroke
(ICD-9 code = 436) identiﬁed from a 10% sub-sample (745,099
cases) of the Health care Cost and Utilization Project (HCUP)
2000 database. The database contains hospitalizations from hos-
pitals in 28 U.S. states. Associations between insurance coverage
(Medicare, Medicaid or private/HMO) and length of stay, in-
hospital death, and discharge destinations were analyzed using
ANOVA, logistic and multinomial regression respectively, con-
trolling for age, gender, race, admission type, admission source,
comorbidities and socioeconomic status. Statistical analyses of
the data were performed using SAS for Windows Version 8.2.
An alpha of <0.05 was required for signiﬁcance. RESULTS:
Insurance type was not statistically signiﬁcant in predicting LOS
after adjusting for other risk factors (p = 0.2095). The interac-
tions between insurance coverage and age, and between insur-
ance and admission source were signiﬁcant. After controlling for
risk factors, insurance type had a signiﬁcant association with in-
hospital death rate (p = 0.0335). Medicare cases were signiﬁ-
cantly more likely to be discharged to home-health care (p =
0.0006), while private/HMO cases were less likely to be dis-
charged to home-health care (p = 0.0071), even after controlling
for risk factors. CONCLUSIONS: Insurance coverage had a 
signiﬁcant association with in-hospital death risk and discharge
destination in patients hospitalized for non-hemorrhagic 
stroke. Further study is needed to elucidate the basis for these
associations.
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OBJECTIVE: The objective of this study was to determine
whether use of a drug-eluting stent (DES) affected the likelihood
of receiving a glycoprotein (GP) IIb/IIIa inhibitor among patients
undergoing percutaneous coronary intervention (PCI) with a
stent. GP IIb/IIIa inhibitors have been used in conjunction with
PCI to reduce ischemic events at or just following the time of the
procedure. Drug-eluting stents, approved by the FDA on April
23, 2003, have been reported to decrease restenosis of a vessel
over the long-term. GPIIa/IIIa inhibitors and drug-eluting stents
